Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

References

• Men P, Tang H, Zhai S. Steps and methods of pharmaceutical health technology assessment. China Medi Insurance. 2015;10(3):57–59.
   Google Scholar
• Lanting L, Jinlan F, Lin X, et al. Dilemma and way out of health technology assessment in Chinese hospitals. China Hospl Manag. 2019;39(02):7–10.
   Google Scholar
• Green A, Hede SM, Patterson CC, et al. Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetology. 2021;64:2741. doi:10.1007/s00125-021-05571-8
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas; 2021. Available fromhttps://diabetesatlas.org/atlas/tenth-edition/. Accessed January 17, 2022.
   Google Scholar
• Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global burden of disease study 2021. Lancet. 2023;402:203.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Obesity and overweight [OL]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed June 09, 2021.
   Google Scholar
• Gavin JR 3rd, Rodbard HW, Fox KM, et al. Association of overweight and obesity with health status, weight management, and exercise behaviors among individuals with type 2 diabetes mellitus or with cardiometabolic risk factors. Risk Manag Healthc Policy. 2009;2:1–7. PMID: 22312203; PMCID: PMC3270907. doi:10.2147/RMHP.S4562
   PubMedGoogle Scholar
• Shi R, Niu Z, Wu B, et al. Study on the risk factors for hyperuricaemia and related vascular complications in patients with type 2 diabetes mellitus. Risk Manag Healthc Policy. 2020;13:1661–1675. PMID: 33061700; PMCID: PMC7518772. doi:10.2147/RMHP.S255042
   PubMed Web of Science ®Google Scholar
• Yanzhen ZHAO, Jing DU. Research progress of GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus[J]. Geriatrics Research. 2021;2(03):55–60.
   Google Scholar
• ElSayed NA, Aleppo G. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care. 2023;46(Supplement_1):S140–S157. doi:10.2337/dc23-S009
   PubMedGoogle Scholar
• Zhigang ZH, Zhanjun DO, Jianping LIU. A rapid guide to drug evaluation and selection in Chinese medical institutions. Medicine Herald. 2023;42(04):447–456.
   Google Scholar
• Wang Z, Liu J, Jianjun L, et al. Guidelines for lipid management in China (2023). Chin J Circu. 2023;38(03):237–271.
   Google Scholar
• Diabetes Branch of Chinese Medical Association. Guidelines for the prevention and treatment of type 2 diabetes in China (2020 Edition). Intl J Endocrinology Metab. 2021;41(05):482–548.
   Google Scholar
• Prevention D, Treatment of Clinical Guidelines Writing Group. Clinical guidelines for prevention and treatment of type 2 diabetes in the elderly in China (2022 Edition). Chin J Diabet. 2022;30(01):2–51.
   Google Scholar
• Mannucci E, Candido R, Monache LD, et al. Italian guidelines for the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis. 2022;59(5):579–622. doi:10.1016/j.numecd.2022.01.027
   Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. PMID: 31497854. doi:10.1093/eurheartj/ehz486
   PubMed Web of Science ®Google Scholar
• Doyle-Delgado K, Chamberlain JJ, Shubrook J H, et al. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American diabetes association’s standards of medical care in diabetes clinical guideline[J]. Ann Internal Med. 2020;173(10):813–821. doi:10.7326/M20-2470
   PubMed Web of Science ®Google Scholar
• Araszkiewicz A, Bandurska-Stankiewicz E, Budzyński A, et al. 2020 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabet. 2020;9(1):1–101.
   Google Scholar
• Gong S, Gao M, Yang H. Interpretation of the 2020 American college of cardiology’s “expert consensus decision path for new treatments to reduce cardiovascular risk in patients with type 2 diabetes”: lowering blood sugar should protect the heart. Chinese General Practice Med. 2021;24(05):509–516.
   Google Scholar
• Tan JWC, Sim D, Ako J, et al. Consensus recommendations by the Asian pacific society of cardiology: optimising cardiovascular outcomes in patients with type 2 diabetes. European Cardiol Review. 2021;16. doi:10.15420/ecr.2020.52
   Web of Science ®Google Scholar
• Center for Capacity Building and Continuing Education of the National Health Commission, Yihong S, Kang C, Xin C, et al. Expert consensus on the diagnosis and treatment of cardiovascular disease in diabetic patients [J]. Chinese J Int Med. 2021;60(5):421–437. doi:10.3760/cma.j.cn112138-20201208-00999
   PubMedGoogle Scholar
• Tsapas A. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Internal Med. 2020;173(4):278–286. doi:10.7326/M20-0864
   PubMed Web of Science ®Google Scholar
• Shen S, Cong W, Changdong D, et al. Systematic evaluation of the efficacy and safety of polyethylene glycol losenatide in the treatment of type 2 diabetes mellitus. Chin J Hospital Pharm. 2021;41(17):1703–1709. doi:10.13286/j.1001-5213.2021.17.02
   Google Scholar
• Xia L, Shen T, Dong W, et al. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: a network meta-analysis. Diabetes Res Clin Pract. 2021;177:108904. doi:10.1016/j.diabres.2021.108904
   PubMed Web of Science ®Google Scholar
• Jing G. Research progress of glucagon-like peptide-1 receptor agonists in cardiovascular complications of type 2 diabetes mellitus[J]. Modern Diag Therap. 2020;31(19):3041–3042+3190.
   Google Scholar
• Xie Z, Yang S, Deng W, et al. Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review. Clin Epidemiol. 2022;14:1463–1476. doi:10.2147/CLEP.S391819
   PubMed Web of Science ®Google Scholar
• Yanlan L, Aiwen H, Guanxu C, et al. Cardiovascular benefit of SGLT-2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes: a systematic review and reticulated Meta-analysis[J]. J Pharm Pract. 2022;40(04):354–358.
   Google Scholar
• Xie C, Zhou J. Recent research progress on the evidence and mechanism of cardiovascular benefit of SGLT2 inhibitors in type 2 diabetes mellitus population. Mod med health. 2021;37(15):2599–2604.
   Google Scholar
• Zhao H, Tang Y, Zheng C, et al. Vitamin D status is independently associated with insulin resistance in patients with type 2 diabetes mellitus. Risk Manag Healthc Policy. 2021;14:1393–1399. PMID: 33854388; PMCID: PMC8039193. doi:10.2147/RMHP.S299963
   PubMed Web of Science ®Google Scholar
• Qiu B, Xiao L, Haotian Y, et al. Application of hospital health technology assessment in the selection and evaluation of sulfonylureas[J]. Chinese J Pharmacy. 2021;56(02):153–161.
   Google Scholar
• Xie Z, Li J, Yang S, et al. A health technology assessment based on Chinese guidelines: glucagon-like peptide-1 receptor agonist in the treatment of type 2 diabetes complicated with cardiovascular disease. Therap Clinil Risk Manag. 2022;18:889–900. doi:10.2147/TCRM.S375067
   PubMed Web of Science ®Google Scholar